Type 2 diabetes articles for people who want clear, practical guidance on symptoms, diagnosis, blood sugar targets, medicines, food, activity, and long-term risk reduction.Start here for plain-language explainers, safety notes, and care-team questions. Use this information to prepare for conversations with a clinician, not to change prescribed treatment on your own.
A 15,413-person real-world study linked publicly funded flash glucose monitoring with fewer acute diabetes-related hospitalizations, shorter stays, and lower inpatient costs, but its quasi-experimental design cannot prove that monitoring alone caused the improvements.
A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.
A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.
A randomized trial found that automated insulin delivery improved time in range for adults with diabetes and advanced kidney disease, but long-term benefits remain unknown.
The ATTEMPT study found early kidney changes under carefully monitored research conditions, but it does not prove long-term kidney protection or routine use in type 1 diabetes.
A randomized trial found that home-delivered medically tailored groceries improved HbA1c and food security for some Medicaid-insured adults with type 2 diabetes.
A safety update describes a rare eye disorder reported with GLP-1 medicines. Here is what people with diabetes should know about symptoms, uncertainty and urgent care.
BMI remains useful, but new obesity frameworks encourage clinicians to also consider waist-based measurements, health complications, and daily function when assessing people with diabetes.
Recent case reports have raised a rare but serious safety question involving semaglutide, poor intake, rapid weight loss, thiamine deficiency, and neurological symptoms. The evidence shows an association, not proven causation.
The FDA approved monthly Tryngolza for adults with severe hypertriglyceridemia. Here is what people with diabetes should know about its purpose, pancreatitis risk and safety.
